

# J Keith Joung

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/301578/j-keith-joung-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

94  
papers

24,033  
citations

50  
h-index

102  
g-index

102  
ext. papers

29,124  
ext. citations

24.7  
avg, IF

7.43  
L-index

#	Paper	IF	Citations
94	CRISPR-Cas systems for editing, regulating and targeting genomes. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 347-55	44.5	2182
93	High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. <i>Nature Biotechnology</i> , <b>2013</b> , 31, 822-6	44.5	2178
92	Efficient genome editing in zebrafish using a CRISPR-Cas system. <i>Nature Biotechnology</i> , <b>2013</b> , 31, 227-9	44.5	2094
91	High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. <i>Nature</i> , <b>2016</b> , 529, 490-5	50.4	1600
90	Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 279-284	44.5	1371
89	GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. <i>Nature Biotechnology</i> , <b>2015</b> , 33, 187-197	44.5	1275
88	TALENs: a widely applicable technology for targeted genome editing. <i>Nature Reviews Molecular Cell Biology</i> , <b>2013</b> , 14, 49-55	48.7	1072
87	Engineered CRISPR-Cas9 nucleases with altered PAM specificities. <i>Nature</i> , <b>2015</b> , 523, 481-5	50.4	1061
86	Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. <i>Nature Biotechnology</i> , <b>2015</b> , 33, 73-80	44.5	904
85	FLASH assembly of TALENs for high-throughput genome editing. <i>Nature Biotechnology</i> , <b>2012</b> , 30, 460-5	44.5	830
84	CRISPR RNA-guided activation of endogenous human genes. <i>Nature Methods</i> , <b>2013</b> , 10, 977-9	21.6	789
83	Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. <i>Nature Biotechnology</i> , <b>2014</b> , 32, 569-76	44.5	738
82	Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. <i>Nature</i> , <b>2017</b> , 550, 407-410	50.4	619
81	Gene therapy comes of age. <i>Science</i> , <b>2018</b> , 359,	33.3	598
80	Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 869-74	44.5	415
79	CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. <i>Nature Methods</i> , <b>2017</b> , 14, 607-614	21.6	397
78	Broadening the targeting range of <i>Staphylococcus aureus</i> CRISPR-Cas9 by modifying PAM recognition. <i>Nature Biotechnology</i> , <b>2015</b> , 33, 1293-1298	44.5	381

77	CRISPResso2 provides accurate and rapid genome editing sequence analysis. <i>Nature Biotechnology</i> , <b>2019</b> , 37, 224-226	44.5	326
76	Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases. <i>Nature Reviews Genetics</i> , <b>2016</b> , 17, 300-12	30.1	305
75	Pathways disrupted in human ALS motor neurons identified through genetic correction of mutant SOD1. <i>Cell Stem Cell</i> , <b>2014</b> , 14, 781-95	18	300
74	Targeted disruption of DNMT1, DNMT3A and DNMT3B in human embryonic stem cells. <i>Nature Genetics</i> , <b>2015</b> , 47, 469-78	36.3	288
73	Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. <i>Nature</i> , <b>2019</b> , 569, 433-437	50.4	270
72	Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. <i>Cell</i> , <b>2013</b> , 155, 1507-20	56.2	255
71	Activation of prokaryotic transcription through arbitrary protein-protein contacts. <i>Nature</i> , <b>1997</b> , 386, 627-30	50.4	253
70	Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. <i>Nature Biotechnology</i> , <b>2019</b> , 37, 276-282	44.5	235
69	An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities. <i>Nature Biotechnology</i> , <b>2018</b> , 36, 977-982	44.5	224
68	In vivo CRISPR editing with no detectable genome-wide off-target mutations. <i>Nature</i> , <b>2018</b> , 561, 416-419	50.4	202
67	Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. <i>Nature Methods</i> , <b>2014</b> , 11, 429-35	21.6	157
66	CRISPR DNA base editors with reduced RNA off-target and self-editing activities. <i>Nature Biotechnology</i> , <b>2019</b> , 37, 1041-1048	44.5	146
65	Inducible and multiplex gene regulation using CRISPR-Cpf1-based transcription factors. <i>Nature Methods</i> , <b>2017</b> , 14, 1163-1166	21.6	132
64	Discovery of widespread type I and type V CRISPR-Cas inhibitors. <i>Science</i> , <b>2018</b> , 362, 240-242	33.3	129
63	Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. <i>Nature Biomedical Engineering</i> , <b>2018</b> , 2, 38-47	19	127
62	Activities and specificities of CRISPR/Cas9 and Cas12a nucleases for targeted mutagenesis in maize. <i>Plant Biotechnology Journal</i> , <b>2019</b> , 17, 362-372	11.6	125
61	High levels of AAV vector integration into CRISPR-induced DNA breaks. <i>Nature Communications</i> , <b>2019</b> , 10, 4439	17.4	119
60	CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. <i>Nature Biotechnology</i> , <b>2021</b> , 39, 41-46	44.5	116

59	Dimeric CRISPR RNA-Guided FokI-dCas9 Nucleases Directed by Truncated gRNAs for Highly Specific Genome Editing. <i>Human Gene Therapy</i> , <b>2015</b> , 26, 425-31	4.8	106
58	Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , <b>2016</b> , 6, 727-39	24.4	94
57	Therapeutic base editing of human hematopoietic stem cells. <i>Nature Medicine</i> , <b>2020</b> , 26, 535-541	50.5	84
56	Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss. <i>Nature Medicine</i> , <b>2019</b> , 25, 1123-1130	50.5	84
55	Chromatin regulation at the frontier of synthetic biology. <i>Nature Reviews Genetics</i> , <b>2015</b> , 16, 159-71	30.1	76
54	Continuous directed evolution of DNA-binding proteins to improve TALEN specificity. <i>Nature Methods</i> , <b>2015</b> , 12, 939-42	21.6	74
53	A dual-deaminase CRISPR base editor enables concurrent adenine and cytosine editing. <i>Nature Biotechnology</i> , <b>2020</b> , 38, 861-864	44.5	72
52	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , <b>2018</b> , 11, 429-440	10.7	71
51	Reply to Genome editing with modularly assembled zinc-finger nucleases. <i>Nature Methods</i> , <b>2010</b> , 7, 91-92	21.6	70
50	Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. <i>Genes and Development</i> , <b>2014</b> , 28, 1957-75	12.6	66
49	CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. <i>Nature Medicine</i> , <b>2015</b> , 21, 1357-63	50.5	65
48	Engineering designer transcription activator-like effector nucleases (TALENs) by REAL or REAL-Fast assembly. <i>Current Protocols in Molecular Biology</i> , <b>2012</b> , Chapter 12, Unit 12.15	2.9	65
47	Allele-Specific CRISPR-Cas9 Genome Editing of the Single-Base P23H Mutation for Rhodopsin-Associated Dominant Retinitis Pigmentosa. <i>CRISPR Journal</i> , <b>2018</b> , 1, 55-64	2.5	60
46	Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. <i>Genes and Development</i> , <b>2015</b> , 29, 1018-31	12.6	55
45	Efficient CRISPR/Cas9-mediated editing of trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 8275-8298	20.1	49
44	Defining CRISPR-Cas9 genome-wide nuclease activities with CIRCLE-seq. <i>Nature Protocols</i> , <b>2018</b> , 13, 2615-2642	52.8	46
43	A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing. <i>Molecular and Cellular Biology</i> , <b>2015</b> , 35, 789-804	4.8	45
42	Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. <i>Blood</i> , <b>2014</b> , 124, 142-50	2.2	39

41	Open-source guideseq software for analysis of GUIDE-seq data. <i>Nature Biotechnology</i> , <b>2016</b> , 34, 483	44.5	34
40	Optimization of AsCas12a for combinatorial genetic screens in human cells. <i>Nature Biotechnology</i> , <b>2021</b> , 39, 94-104	44.5	34
39	Targeted genome editing in human cells using CRISPR/Cas nucleases and truncated guide RNAs. <i>Methods in Enzymology</i> , <b>2014</b> , 546, 21-45	1.7	33
38	PrimeDesign software for rapid and simplified design of prime editing guide RNAs. <i>Nature Communications</i> , <b>2021</b> , 12, 1034	17.4	32
37	Nodal patterning without Lefty inhibitory feedback is functional but fragile. <i>ELife</i> , <b>2017</b> , 6,	8.9	31
36	CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells. <i>Nature Biotechnology</i> , <b>2021</b> ,	44.5	30
35	Response to "Unexpected mutations after CRISPR-Cas9 editing in vivo". <i>Nature Methods</i> , <b>2018</b> , 15, 238-239	23.6	25
34	Context influences on TALE-DNA binding revealed by quantitative profiling. <i>Nature Communications</i> , <b>2015</b> , 6, 7440	17.4	22
33	What's changed with genome editing?. <i>Cell Stem Cell</i> , <b>2014</b> , 15, 3-4	18	21
32	Engineering customized TALE nucleases (TALENs) and TALE transcription factors by fast ligation-based automatable solid-phase high-throughput (FLASH) assembly. <i>Current Protocols in Molecular Biology</i> , <b>2013</b> , Chapter 12, Unit 12.16	2.9	20
31	CRISPR-SURF: discovering regulatory elements by deconvolution of CRISPR tiling screen data. <i>Nature Methods</i> , <b>2018</b> , 15, 992-993	21.6	17
30	Impact of Genetic Variation on CRISPR-Cas Targeting. <i>CRISPR Journal</i> , <b>2018</b> , 1, 159-170	2.5	16
29	IKB kinase $\beta$ (IKBKB) mutations in lymphomas that constitutively activate canonical nuclear factor $\kappa$ B (NFB) signaling. <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 26960-26972	5.4	16
28	Unwanted mutations: Standards needed for gene-editing errors. <i>Nature</i> , <b>2015</b> , 523, 158	50.4	15
27	Engineering designer nucleases with customized cleavage specificities. <i>Current Protocols in Molecular Biology</i> , <b>2011</b> , Chapter 12, Unit 12.13	2.9	15
26	Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway. <i>Oncotarget</i> , <b>2017</b> , 8, 43733-43751	3.3	15
25	A Code of Ethics for Gene Drive Research. <i>CRISPR Journal</i> , <b>2021</b> , 4, 19-24	2.5	14
24	Temporal and Spatial Post-Transcriptional Regulation of Zebrafish mRNA by Long Noncoding RNA During Brain Vascular Assembly. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 1562-1575	9.4	12

23	Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model. <i>PLoS Genetics</i> , <b>2015</b> , 11, e1005239	6	11
22	Optimization of AsCas12a for combinatorial genetic screens in human cells		11
21	Genome Editing in Human Cells Using CRISPR/Cas Nucleases. <i>Current Protocols in Molecular Biology</i> , <b>2015</b> , 112, 31.3.1-31.3.18	2.9	10
20	Identifying and modifying protein-DNA and protein-protein interactions using a bacterial two-hybrid selection system. <i>Journal of Cellular Biochemistry</i> , <b>2001</b> , Suppl 37, 53-7	4.7	10
19	Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	10
18	Genome editing: a tool for research and therapy: towards a functional understanding of variants for molecular diagnostics using genome editing. <i>Nature Medicine</i> , <b>2014</b> , 20, 1103-4	50.5	9
17	PrimeDesign software for rapid and simplified design of prime editing guide RNAs		8
16	Technologies and Computational Analysis Strategies for CRISPR Applications. <i>Molecular Cell</i> , <b>2020</b> , 79, 11-29	17.6	7
15	CRISPR adenine and cytosine base editors with reduced RNA off-target activities		6
14	Analysis and comparison of genome editing using CRISPResso2		4
13	Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources <b>2020</b> , 8,		4
12	Scalable characterization of the PAM requirements of CRISPR-Cas enzymes using HT-PAMDA. <i>Nature Protocols</i> , <b>2021</b> , 16, 1511-1547	18.8	4
11	Mutant Allele-Specific CRISPR Disruption in DYT1 Dystonia Fibroblasts Restores Cell Function. <i>Molecular Therapy - Nucleic Acids</i> , <b>2020</b> , 21, 1-12	10.7	3
10	Zebrafish Deficiency Impairs Retinal Patterning and Oculomotor Function. <i>Journal of Neuroscience</i> , <b>2020</b> , 40, 143-158	6.6	3
9	Disruption of the kringle 1 domain of prothrombin leads to late onset mortality in zebrafish. <i>Scientific Reports</i> , <b>2020</b> , 10, 4049	4.9	2
8	Global-scale CRISPR gene editor specificity profiling by ONE-seq identifies population-specific, variant off-target effects		2
7	Genome-wide functional perturbation of human microsatellite repeats using engineered zinc finger transcription factors. <i>Cell Genomics</i> , <b>2022</b> , 2, 100119		2
6	Factor X Mutant Zebrafish Tolerate a Severe Hemostatic Defect in Early Development Yet Develop Lethal Hemorrhage in Adulthood. <i>Blood</i> , <b>2015</b> , 126, 426-426	2.2	1

5	Augmenting and directing long-range CRISPR-mediated activation in human cells. <i>Nature Methods</i> , <b>2021</b> , 18, 1075-1081	21.6	1
4	CRISPR-Cas9 treatment partially restores amyloid- $\beta$ 2/40 in human fibroblasts with the Alzheimer's disease M146L mutation.. <i>Molecular Therapy - Nucleic Acids</i> , <b>2022</b> , 28, 450-461	10.7	1
3	Defining genome-wide CRISPR-Cas genome-editing nuclease activity with GUIDE-seq. <i>Nature Protocols</i> , <b>2021</b> , 16, 5592-5615	18.8	0
2	Combined +58 and +55 BCL11A enhancer Editing Yields Exceptional Efficiency, Specificity and HbF Induction in Human and NHP Preclinical Models. <i>Blood</i> , <b>2021</b> , 138, 1852-1852	2.2	
1	A Zebrafish Model Of Antithrombin III Deficiency Displays Bleeding and Thrombosis Secondary To Disseminated Intravascular Coagulation. <i>Blood</i> , <b>2013</b> , 122, 200-200	2.2	